• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Concert Pharmaceutic (NQ: CNCE )

    N/A UNCHANGED
    Last Price Updated: 4:00 PM EST, Mar 3, 2023 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Concert Pharmaceutic

    < Previous 1 2 Next >
    Concert Pharmaceuticals Maintains Deuruxolitinib Breakthrough Therapy Designation from FDA for the Treatment of Alopecia Areata
    From Concert Pharmaceuticals, Inc.
    Via Business Wire
    CNCE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Concert Pharmaceuticals, Inc. Is Fair to Shareholders
    From Halper Sadeh LLC
    Via Business Wire
    CONCERT PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Concert Pharmaceuticals, Inc. - CNCE
    From Kahn Swick & Foti, LLC
    Via Business Wire
    CNCE Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Concert Pharmaceuticals, Inc. Is Fair to Shareholders
    From Halper Sadeh LLC
    Via Business Wire
    Sun Pharma to Acquire Concert Pharmaceuticals, Advancing the Potential Treatment of Alopecia Areata
    From Concert Pharmaceuticals
    Via Business Wire
    Is Ardelyx is A Buy After Slip in Early 2022
    Ardelyx is relatively new to the market and was doing well until a small drug approval issue last year. Strong earnings and smart partnerships could save them 
    Via MarketBeat
    Exposures Product Safety
    Concert Pharmaceuticals Announces Presentation of Deuruxolitinib THRIVE-AA1 Phase 3 Study Results in Alopecia Areata During World Congress for Hair Research
    From Concert Pharmaceuticals, Inc.
    Via Business Wire
    Concert Pharmaceuticals to Participate in Fireside Chat at the Jefferies London Healthcare Conference
    From Concert Pharmaceuticals
    Via Business Wire
    Concert Pharmaceuticals Reports Third Quarter 2022 Financial Results
    From Concert Pharmaceuticals, Inc.
    Via Business Wire
    Concert Pharmaceuticals to Report Third Quarter 2022 Results on November 7, 2022
    From Concert Pharmaceuticals, Inc.
    Via Business Wire
    Concert Pharmaceuticals Announces Presentation of CTP-543 THRIVE-AA1 Phase 3 Data in Alopecia Areata During Late Breaking Session at EADV Congress
    From Concert Pharmaceuticals, Inc.
    Via Business Wire
    Concert Pharmaceuticals to Present at H.C. Wainwright Global Investment Conference
    From Concert Pharmaceuticals, Inc.
    Via Business Wire
    Bridges and Landmarks Across the USA Will Illuminate Blue Throughout the Month of September for Alopecia Areata
    From Concert Pharmaceuticals, Inc.
    Via Business Wire
    Concert Pharmaceuticals Announces That Results From CTP-543 THRIVE‑AA1 Phase 3 Trial in Patients With Alopecia Areata Selected for Late Breaking Presentation at EADV Congress
    From Concert Pharmaceuticals, Inc.
    Via Business Wire
    Concert Pharmaceuticals Announces Exercise of Warrants Under Existing Financing Arrangement
    From Concert Pharmaceuticals, Inc.
    Via Business Wire
    Concert Pharmaceuticals Reports Second Quarter 2022 Financial Results
    From Concert Pharmaceuticals, Inc.
    Via Business Wire
    Concert Pharmaceuticals Reports Positive Topline Results for Second CTP‑543 Phase 3 Clinical Trial in Alopecia Areata
    From Concert Pharmaceuticals, Inc.
    Via Business Wire
    Concert Pharmaceuticals to Report Second Quarter 2022 Results on August 4, 2022
    From Concert Pharmaceuticals, Inc.
    Via Business Wire
    Concert Pharmaceuticals to Participate in Fireside Chat at The JMP Securities Life Sciences Conference
    From Concert Pharmaceuticals, Inc.
    Via Business Wire
    Phase 2 Dose‑Ranging Clinical Trial Results of CTP‑543 in Patients with Alopecia Areata published in the Journal of the American Academy of Dermatology
    From Concert Pharmaceuticals, Inc.
    Via Business Wire
    Concert Pharmaceuticals Raises Gross Proceeds of $66.4 Million Through Public Offering and Exercise of Warrants
    From Concert Pharmaceuticals, Inc.
    Via Business Wire
    Concert Pharmaceuticals Announces Pricing of Public Offering
    From Concert Pharmaceuticals, Inc.
    Via Business Wire
    Concert Pharmaceuticals Announces Proposed Public Offering of Common Stock
    From Concert Pharmaceuticals, Inc.
    Via Business Wire
    Concert Pharmaceuticals Reports Positive Topline Results for First CTP-543 Phase 3 Clinical Trial in Alopecia Areata
    From Concert Pharmaceuticals, Inc.
    Via Business Wire
    Concert Pharmaceuticals Reports First Quarter 2022 Financial Results
    From Concert Pharmaceuticals, Inc.
    Via Business Wire
    Concert Pharmaceuticals to Report First Quarter 2022 Results on May 5, 2022
    From Concert Pharmaceuticals, Inc.
    Via Business Wire
    Concert Pharmaceuticals to Report Fourth Quarter 2021 Results on March 3, 2022
    From Concert Pharmaceuticals, Inc.
    Via Business Wire
    Concert Pharmaceuticals Completes Enrollment in THRIVE-AA2 Phase 3 Clinical Trial Evaluating CTP-543 for Alopecia Areata
    From Concert Pharmaceuticals, Inc.
    Via Business Wire
    Concert Pharmaceuticals to Present at H.C. Wainwright BIOCONNECT Virtual Conference
    From Concert Pharmaceuticals, Inc.
    Via Business Wire
    Concert Pharmaceuticals to Participate in Fireside Chat at Jefferies London Healthcare Conferences
    From Concert Pharmaceuticals, Inc.
    Via Business Wire
    < Previous 1 2 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.